ES2524320T3 - Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo - Google Patents

Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo Download PDF

Info

Publication number
ES2524320T3
ES2524320T3 ES08703408.8T ES08703408T ES2524320T3 ES 2524320 T3 ES2524320 T3 ES 2524320T3 ES 08703408 T ES08703408 T ES 08703408T ES 2524320 T3 ES2524320 T3 ES 2524320T3
Authority
ES
Spain
Prior art keywords
thrombus
prevention
treatment
composition
disease associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08703408.8T
Other languages
English (en)
Inventor
Hiroyuki Kawano
Ryo Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2524320T3 publication Critical patent/ES2524320T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion para su uso en la prevenciOn o el tratamiento de una enfermedad asociada con trombo o embolo que comprende, como principios activos que van a aplicarse en combinaciOn, al menos uno seleccionado del grupo que consiste en clopidogrel y sus sales farmaceuticamente aceptables y al menos uno seleccionado del grupo que consiste en acido eicosapentaenoico asi como sus esteres y sales farmaceuticamente aceptables, en la que la aplicaciOn en combinaci6n incluye administrar una formulaciOn que contiene ambos principios activos, y administrar los dos principios activos como formulaciones separadas simultaneamente, o por separado con un determinado retraso en el tiempo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
    imagen2
ES08703408.8T 2007-01-17 2008-01-17 Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo Active ES2524320T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007008590 2007-01-17
JP2007008590 2007-01-17
PCT/JP2008/050554 WO2008088030A1 (ja) 2007-01-17 2008-01-17 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物

Publications (1)

Publication Number Publication Date
ES2524320T3 true ES2524320T3 (es) 2014-12-05

Family

ID=39636031

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08703408.8T Active ES2524320T3 (es) 2007-01-17 2008-01-17 Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo

Country Status (6)

Country Link
US (1) US20100113506A1 (es)
EP (1) EP2119443B1 (es)
JP (1) JP5345402B2 (es)
CA (1) CA2675836C (es)
ES (1) ES2524320T3 (es)
WO (1) WO2008088030A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007609A (es) * 2008-01-10 2010-08-04 Takeda Pharmaceutical Formulacion de capsula.
TW201017149A (en) * 2008-08-06 2010-05-01 Invitrox Inc Use of focused light scattering techniques in biological applications
US20110152223A1 (en) * 2008-08-22 2011-06-23 Junichi Hirahashi Therapeutic agent for anca-related vasculitis
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011065444A1 (ja) * 2009-11-27 2011-06-03 学校法人東海大学 抗血栓剤
JPWO2012067152A1 (ja) * 2010-11-16 2014-05-12 三菱化学株式会社 ＥｎｄｏｔｈｅｌｉａｌＰｒｏｔｅｉｎＣＲｅｃｅｐｔｏｒ蛋白質による脳梗塞の検査方法
NZ778131A (en) * 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) * 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130095179A1 (en) * 2011-09-15 2013-04-18 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
KR20140001648A (ko) * 2012-06-28 2014-01-07 주식회사 엘지생명과학 안정성이 개선된 클로피도그렐 황산수소염의 경구용 제제 제품
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
JP7468983B2 (ja) * 2015-06-03 2024-04-16 ウィスコンシン アラムニ リサーチ ファンデーション 虚血性疾患または虚血性損傷を処置するための心臓線維芽細胞由来細胞外マトリックスおよびその注射可能製剤
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
KR102532121B1 (ko) * 2017-10-18 2023-05-12 고려제약주식회사 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
CN112967750B (zh) * 2021-03-23 2024-03-29 复旦大学附属中山医院 一种预测氯吡格雷抗血小板疗效的模型及其应用
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125602D0 (en) * 1991-12-02 1992-01-29 Efamol Holdings Method of preventing reocclusion of arteries
JPH08157362A (ja) 1994-12-06 1996-06-18 Sankyo Co Ltd 油性物質含有固形製剤の製法
JP3418274B2 (ja) 1995-06-05 2003-06-16 日本化薬株式会社 口腔内感触の良好な錠剤
JPH1099046A (ja) 1996-09-30 1998-04-21 Nof Corp 粉末組成物の製造方法
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
WO2003026636A1 (en) * 2001-09-26 2003-04-03 Mitsubishi Pharma Corporation Thrombus/thrombogenesis inhibitors
CA2499501A1 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
JP2005021124A (ja) 2003-07-02 2005-01-27 Kyukyu Yakuhin Kogyo Kk 口腔用フィルム製剤
RU2396289C2 (ru) * 2004-08-13 2010-08-10 Рева Медикал, Инк. Саморассасывающиеся рентгеноконтрастные по своей природе полимеры для многоцелевого использования
JP2009532663A (ja) * 2006-02-16 2009-09-10 レリアント ファーマスーティカルズ インコーポレイテッド ω−３脂肪酸を用いた、痴呆、脳血管性痴呆、パーキンソン痴呆、アルツハイマー病及び／又は軽度認知障害の治療により利益を得ると考えられる患者を同定し、治療する方法

Also Published As

Publication number Publication date
CA2675836C (en) 2016-10-11
JPWO2008088030A1 (ja) 2010-05-13
WO2008088030A1 (ja) 2008-07-24
EP2119443B1 (en) 2014-08-20
JP5345402B2 (ja) 2013-11-20
US20100113506A1 (en) 2010-05-06
CA2675836A1 (en) 2008-07-24
EP2119443A4 (en) 2010-03-03
EP2119443A1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
MX2014014117A (es) Compuestos de d-aminoacidos para enfermedades del higado.
BR112014031837A2 (pt) formulações de progesterona
MX2012005365A (es) Formulaciones de tableta de liberacion inmediata.
CO2021011652A2 (es) Ésteres de ácido graso como agentes anti-malassezia
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
CO6470839A2 (es) Composiciones farmacéuticas que contienen epa y un agente cardiovascular y métodos de emplearlas
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
AR061289A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
ECSP099039A (es) Esteres de dha y su utilización en el tratamiento y la prevención de enfermedades cardiovasculares
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
CL2012003521A1 (es) Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.
CL2015003596A1 (es) Formulación de liberación modificada
MX2021002902A (es) Composicion farmaceutica para prevenir o tratar la enfermedad del higado graso no alcoholico, que contiene ligando gpr119 como principio activo.
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico